Asthma

Most Effective Atopic Dermatitis Treatments May Also Be Most Harmful

Retrieved on: 
Wednesday, February 21, 2024
Atopic dermatitis, AAAAI, MEDLINE, Research, Multimedia, Conjunctivitis, Meta-analysis, Ciclosporin, Physician, Quality of life, Asthma, Methotrexate, Skin, Annual general meeting, GREAT, Light, Sleep, Patient, Journal, Dermatitis, The Hills Shire, Azathioprine, American Academy, Pharmaceutical industry

"Atopic dermatitis is the most common inflammatory skin condition with an increasing number of available systemic interventions.

Key Points: 
  • "Atopic dermatitis is the most common inflammatory skin condition with an increasing number of available systemic interventions.
  • Competing treatment options exist for atopic dermatitis, but uncertainty regarding their comparative effectiveness still remains, the study showed.
  • Researchers examined the benefits and harms of all systemic and phototherapy treatments for atopic dermatitis in this network meta-analysis.
  • In randomized, controlled trials addressing systemic and phototherapy treatments for atopic dermatitis from MEDLINE, EMBASE, CENTRAL, Web of Science and GREAT, researchers performed Bayesian random-effects network meta-analyses on atopic dermatitis severity, itch severity, sleep disturbance, quality of life, exacerbations and adverse events.

BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs

Retrieved on: 
Wednesday, February 21, 2024
Allergy, ABBV, Senior, Woman, Injection, Research, ALS, Paratriathlon, Headache, Neck pain, Workplace, Education, Catherine Disher, Dream, Vitamin, Small business, Dizziness, Mentorship, Asthma, AbbVie, Weakness, Risk, AB toxin, Pain, Face, Human, COMMUNITY, BIPOC, Postal, Eyebrow, Confidence, Rash, Skin infection, Breast milk, Burnout, Myasthenia gravis, Eyelid, Lambert–Eaton myasthenic syndrome, Medication, Wheeze, Fatigue, Xerostomia, Partnership, Pharmaceutical industry

IRVINE, Calif., Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program supporting women entrepreneurs. BOTOX® Cosmetic partnered with IFundWomen to launch the program in 2023, and in the second year, will award a new group of 20 women entrepreneurs each with $25,000 grants to fund and grow their businesses. Additionally, BOTOX® Cosmetic continues to support these businesses through mentorship, coaching, crowdfunding, and community.

Key Points: 
  • FOR THE SECOND YEAR, BOTOX® COSMETIC WILL HELP WOMEN ENTREPRENEURS CLOSE THE CONFIDENCE GAP THROUGH FUNDING, MENTORSHIP, COACHING, AND COMMUNITY
    IRVINE, Calif., Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program supporting women entrepreneurs.
  • We are grateful to learn from them and thrilled to continue this program into a second year with a new cohort of extraordinary women entrepreneurs."
  • I am forever grateful to this program for connecting me to a group of women entrepreneurs who together are helping to bridge the Confidence Gap.
  • Starting today, women entrepreneurs across the country can apply for the BOTOX® Cosmetic x IFundWomen grant at www.botoxcosmetic.com/realimpact for the chance to be one of 20 recipients.

Boosting Health for Children: Transition to Electric Vehicles and Clean Power Would Prevent 2.7 Million Asthma Attacks in U.S. Kids

Retrieved on: 
Wednesday, February 21, 2024
Air pollution, Weather, Transport, Vehicle emissions control, Asthma, Carbon, Risk, Atmosphere of Earth, Health, Climate change, American Lung Association, Infant, Allergen, EPA, Wildfire, Renewable energy

CHICAGO, Feb. 21, 2024 /PRNewswire/ -- A new report, "Boosting Health for Children: Benefits of Zero-Emission Transportation and Electricity," released today by the American Lung Association, highlights that a widespread transition to zero-emission vehicles and electricity would dramatically improve the health of children across the U.S. The transition would prevent 2.79 million pediatric asthma attacks and millions of other respiratory symptoms and save hundreds of infant lives by 2050.

Key Points: 
  • The transition would prevent 2.79 million pediatric asthma attacks and millions of other respiratory symptoms and save hundreds of infant lives by 2050.
  • It also projects that the nation's electric grid will be powered by clean, non-combustion renewable energy by 2035.
  • In fact, 1.7 million children with asthma live in counties that received an "F" for at least one pollutant.
  • Policymakers have the power to support children's health by cutting harmful air pollution and climate change that threatens their future.

PH Labelling of Skin Cleansers Can Lead to Better Options for People with Atopic Dermatitis

Retrieved on: 
Tuesday, February 20, 2024
Atopic dermatitis, Allergy, Skin, AAAAI, Research, Asthma, Skin care, Patient, Journal, Water, American Academy, Cosmetics

MILWAUKEE, Feb. 20, 2024 /PRNewswire-PRWeb/ -- Atopic dermatitis patients may find better results using liquid synthetic detergents according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting.

Key Points: 
  • "Shopping for skin cleanser products for Atopic Dermatitis can be dizzying with so many options available and different claims made on the labels," said primary author Adil Khan, MD.
  • In particular, liquid synthetic cleansers most closely mimic normal skin pH."
  • Skin with atopic dermatitis (AD) changes pH from acidic to alkaline, which contributes to skin-barrier dysfunction.
  • These findings suggest that patients with atopic dermatitis may find better results with liquid syndets compared to other skincare options.

Rebamipide May Combat Low-Grade Inflammation in Post-COVID-19 Syndrome Patients

Retrieved on: 
Monday, February 19, 2024
Group 1, Coronavirus, AAAAI, Research, SARS-CoV-2, Doctor of Philosophy, Multimedia, Inflammation, Nonsteroidal anti-inflammatory drug, Enterocyte, Asthma, ELISA, Radical, Arthralgia, Group 2, COVID-19, CRP, COVID, Patient, Journal, Rehabilitation, Plasma, Ageing, Rebamipide, American Academy, Pharmaceutical industry

MILWAUKEE, Feb. 19, 2024 /PRNewswire-PRWeb/ -- Rebamipide may be useful for rehabilitation of patients with SARS-CoV-2 post-COVID syndrome according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, DC, this month.

Key Points: 
  • "This study revealed higher levels of lipopolysaccharide-binding protein, and lower levels of bacterial permeability protein in patients with post COVID syndrome.
  • Rebamipide, by reducing intestinal permeability, reduces endotoxin load, lowering the level of low-grade inflammation.
  • To explore Rebamipide's usefulness for rehabilitating SARS-CoV-2 post-COVID syndrome patients, researchers examined 62 patients, aged 42-55 years with post-COVID-19 syndrome using nonsteroidal anti-inflammatory drugs for joint pain.
  • Given the effects of SARS-CoV-2 on enterocytes, the results suggest that Rebamipide may be useful for rehabilitation of patients with SARS-CoV-2 post-COVID syndrome.

RS Is Fueling the Future of Commercial EV Charging Infrastructure

Retrieved on: 
Monday, February 19, 2024
Sentinel, EVS, Collection, EV, HMIS, Air filter, Phoenix Contact, ARM, Original equipment manufacturer, Asthma, RS Group, Life, Communication, Safety, Series, Climate change, RS Group plc, AAA, Electronics, Primary energy, Lung cancer, Beijer Electronics, Travel, AC, Fireworks

FORT WORTH, Texas, Feb. 19, 2024 /PRNewswire/ -- RS, a trading brand of RS Group plc (LSE: RS1), a global provider of product and service solutions for industrial customers, offers an extensive portfolio of electrical and electronic component and device solutions engineered to satisfy the unique demands of EV charging infrastructure and encourage increased commercial and consumer adoption.

Key Points: 
  • RS offers an extensive range of products essential to the continued evolution of commercial EV charging infrastructure.
  • EV charging infrastructure is only as good as the technology it's based on — all the way down to the component and device level — and the RS portfolio of alternative energy solutions includes an extensive range of electrical and electronic products essential to the continued evolution of commercial EV charging infrastructure, including contactors, industrial transformers, DC power modules, EV charging control boards, EV charging station test adapters, and HMIs from many of the industry's most trusted suppliers.
  • In EV charging infrastructure, they're used to simplify the charging process, improve safety, and enhance the user experience.
  • For more information about RS solutions for EV charging infrastructure and related application areas, visit our alternative energy page and the links embedded here, and check out our collection of expert insights into and advice about the industry , including the new "Fueling the Future of Commercial EV Charging Infrastructure" article by Miguel Gudino, an Associate Application Engineer at RS.

FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure

Retrieved on: 
Friday, February 16, 2024
Human services, Allergy, Fever, Division, Research, Food allergy, Polyp (medicine), Sinusitis, Hazelnut, Cosmetics, Multimedia, Hypersensitivity, Dietary supplement, Critical care, FDA, Food, Immunoglobulin E, Infection, Asthma, Anaphylaxis, Peanut allergy, Skin, Vomiting, Emergency, Vaccine, Risk, Animal, Safety, Heated tobacco product, Arthralgia, History, Milk, Malignancy, Rash, Public, Patient, Adrenaline, Peanut, Priority review

Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.

Key Points: 
  • Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.
  • "While it will not eliminate food allergies or allow patients to consume food allergens freely, its repeated use will help reduce the health impact if accidental exposure occurs."
  • Current treatment requires strict avoidance of the food(s) the patient is allergic to, and prompt administration of epinephrine to treat anaphylaxis should accidental exposures occur.
  • Xolair is the first FDA-approved medication to reduce allergic reactions to more than one type of food after accidental exposure.

FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies

Retrieved on: 
Friday, February 16, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Infection, Allergy, Bangladesh Technical Education Board, AAAAI, Johns Hopkins Children's Center, Emergency, Hazelnut, NIAID, American Academy, Omalizumab, NIH, Friends, Food, Immunoglobulin E, News, Asthma, Anaphylaxis, FARE, Annual general meeting, Prevalence, Roche, Milk, ROG, AAFA, Patient, Family, Phase, Ageing, Education

People taking Xolair for food allergies should continue to avoid all foods they are allergic to (commonly referred to as “food allergen avoidance”).

Key Points: 
  • People taking Xolair for food allergies should continue to avoid all foods they are allergic to (commonly referred to as “food allergen avoidance”).
  • Immunoglobulin E (IgE)-mediated food allergies are the most common type and are typically characterized by the rapid onset of symptoms following exposure to certain food allergens.
  • Xolair is the first and only FDA-approved medicine to reduce allergic reactions in people with one or more food allergies.
  • About 3.4 million children and 13.6 million adults in the U.S. have been diagnosed with IgE-mediated food allergies, based on estimates for 2024.

FDA approves Xolair® (omalizumab) as first and only medicine for children and adults with one or more food allergies

Retrieved on: 
Friday, February 16, 2024
Infection, Allergy, Bangladesh Technical Education Board, AAAAI, Johns Hopkins Children's Center, Emergency, Food allergy, Hazelnut, NIAID, NIH, FDA, Friends, Food, Immunoglobulin E, News, Anaphylaxis, FARE, Annual general meeting, Prevalence, Milk, AAFA, Patient, Family, Medicine, Novartis, Asthma, Phase, Ageing, Education, American Academy

People taking Xolair for food allergies should continue to avoid all foods they are allergic to (commonly referred to as "food allergen avoidance").

Key Points: 
  • People taking Xolair for food allergies should continue to avoid all foods they are allergic to (commonly referred to as "food allergen avoidance").
  • Immunoglobulin E (IgE)-mediated food allergies are the most common type and are typically characterized by the rapid onset of symptoms following exposure to certain food allergens3.
  • Xolair is the first and only FDA-approved medicine to reduce allergic reactions in people with one or more food allergies.
  • "Given the growing prevalence of food allergies, this news offers hope to the many children and adults who may benefit from a new way to help manage their food allergies."

The Development of Allergic Disease Not Associated with Prenatal PM2.5 Air Pollution Exposure

Retrieved on: 
Friday, February 16, 2024
Wheeze, Incidence, Air pollution, AAAAI, Research, Food allergy, Multimedia, Asthma, Allergic rhinitis, Pregnancy, University, Health, Particulates, Patient, Journal, Dermatitis, American Academy, Cochineal

MILWAUKEE, Feb. 16, 2024 /PRNewswire-PRWeb/ -- No significant association was found between ambient particulate matter (PM2.5) exposure and incidences of asthma, allergic rhinitis or eczema according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting in Washington, DC this month.

Key Points: 
  • In settings of low overall air pollution levels, differences in the development of allergic disease by race were not significant in new birth cohort.
  • Black and Latin populations have been shown to have higher exposure to PM2.5 air pollution due to structural racism.
  • To assess the risks of prenatal air pollution exposure in minority populations, researchers recruited 1,261 mother-infant pairs from the University of Colorado.
  • The results found no evidence of an association between prenatal PM2.5 air pollution exposure and development of allergic disease or differences in air pollution exposure by race in a setting of low overall air pollution levels.